Records 1 - 7
| Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma.
Journal of clinical and translational hepatology 2021 Apr 9 (2): 169-179.
Huo Junyu, Wu Liqun, Zang Yunj
| Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Oncotarget 2016 May .
Zhou Jun, Wen Qiang, Li Sai-Fei, Zhang Yun-Fei, Gao Na, Tian Xin, Fang Yan, Gao Jie, Cui Ming-Zhu, He Xiao-Pei, Jia Lin-Jing, Jin Han, Qiao Hai-Li
| Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation.
South Asian journal of cancer 2014 Jul 3 (3): 154-8.
Paul Sayan, Chaudhuri Tamojit, Pant M C, Parmar D, Srivastava Kir
| Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.
Mutation research 2010 Feb 684 (1-2): 49-55.
Yadav Sunishtha S, Ruwali Munindra, Pant Mohan C, Shukla Pragya, Singh Ram L, Parmar Devend
| The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese.
Clinica chimica acta; international journal of clinical chemistry 2007 May 380 (1-2): 191-6.
Liao Ling-Hong, Zhang Hao, Lai Man-Po, Lau Kwok-Wai, Lai Albert Kai-Cheong, Zhang Jin-Hui, Wang Qi, Wei Wei, Chai Jian-Hua, Lung Maria Li, Tai Susan S W, Wu Madeli
| No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
Pharmacogenetics and genomics 2005 Oct 15 (10): 713-21.
McGreavey Louise E, Turner Faye, Smith Gillian, Boylan Katherine, Timothy Bishop D, Forman David, Roland Wolf C, Barrett Jennifer H,
| Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer.
Indian journal of cancer 0 48 (2): 223-9.
Paul S, Pant M C, Parmar D, Verma